$HGRAF
There are few companies that have a technology and IP driven moat, necessary regulatory approvals (EPA/EU Reach), capital to scale and product versatility with potential demand across countless end markets.
The above is being held back only by customer contracts.
This $HGRAF story is one of the most exciting out there.
EPA approval + UK/EU reach gives them access to the markets that matter.
This is a credibility story for an OTC. Customer contracts need to come in the next 3-6 months and this stock will run like crazy (nasdaq aside).
@thatkidbigmike He’s doing a bit better than others (2.7% shares outstanding) but still not enough insider ownership given catalysts ahead if confidence level is high.
$HGRAF
Give us:
-EPA approval: hard to forecast as they are at behest of the gov’t. @RonaldVolusus shared the publicly available info with best date.
-Meaningful customer contract: break pipeline into clear funnel.
-Insider buying: why isn’t exec + BoD borrowing to buy?